Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leritrelvir in mild to moderate COVID-19
NCT05620160Phase 3Completed
- Sponsor
- Raynovent Biotech
- Start
- Nov 2022
- Primary completion
- Jan 2023
- Modality
- Covalent Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of leritrelvir in coronavirus disease 2019 (COVID-19), sponsored by Raynovent Biotech. Started Nov 2022; status: completed.
02
Drugs
leritrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05620160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620160.